ZNTL Key Statistics, Chart & Performance
The current stock price of ZNTL is 1.41 USD. In the past month the price increased by 10.16%. In the past year, price decreased by -54.37%.
ZNTL Latest News, Press Relases and Analysis
ZNTL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.61 | 394.34B | ||
| AMGN | AMGEN INC | 14.69 | 172.98B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.46 | 112.15B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.62 | 73.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 843.18 | 56.81B | ||
| INSM | INSMED INC | N/A | 41.92B | ||
| NTRA | NATERA INC | N/A | 33.00B | ||
| BIIB | BIOGEN INC | 10.78 | 26.47B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.17 | 20.65B | ||
| INCY | INCYTE CORP | 15.06 | 18.98B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.16B |
Related stock screener links
About ZNTL
Company Profile
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in San Diego, California and currently employs 166 full-time employees. The company went IPO on 2020-04-03. The firm is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The firm is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.
Company Info
ZENTALIS PHARMACEUTICALS INC
10275 Science Center Drive, Suite 200
San Diego CALIFORNIA 10018 US
CEO: Anthony Y. Sun
Employees: 166
Phone: 18582634333
ZENTALIS PHARMACEUTICALS INC / ZNTL FAQ
What does ZENTALIS PHARMACEUTICALS INC do?
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in San Diego, California and currently employs 166 full-time employees. The company went IPO on 2020-04-03. The firm is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The firm is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.
Can you provide the latest stock price for ZENTALIS PHARMACEUTICALS INC?
The current stock price of ZNTL is 1.41 USD. The price increased by 1.44% in the last trading session.
What is the dividend status of ZENTALIS PHARMACEUTICALS INC?
ZNTL does not pay a dividend.
How is the ChartMill rating for ZENTALIS PHARMACEUTICALS INC?
ZNTL has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does ZENTALIS PHARMACEUTICALS INC belong to?
ZENTALIS PHARMACEUTICALS INC (ZNTL) operates in the Health Care sector and the Biotechnology industry.
Would investing in ZENTALIS PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ZNTL.
Is ZENTALIS PHARMACEUTICALS INC (ZNTL) expected to grow?
The Revenue of ZENTALIS PHARMACEUTICALS INC (ZNTL) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ZNTL Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ZNTL. When comparing the yearly performance of all stocks, ZNTL is a bad performer in the overall market: 89.65% of all stocks are doing better.
ZNTL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ZNTL. While ZNTL seems to be doing ok healthwise, there are quite some concerns on its profitability.
ZNTL Financial Highlights
Over the last trailing twelve months ZNTL reported a non-GAAP Earnings per Share(EPS) of -1.92. The EPS increased by 25.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.48% | ||
| ROE | -58.86% | ||
| Debt/Equity | 0 |
ZNTL Forecast & Estimates
15 analysts have analysed ZNTL and the average price target is 5.42 USD. This implies a price increase of 284.31% is expected in the next year compared to the current price of 1.41.
For the next year, analysts expect an EPS growth of 18.41% and a revenue growth -100% for ZNTL